Frontlight ResearchEarly access
Active, not recruitingNo phase
China S3 PMS: SAPIEN 3 China Post Market Registry Study
Key facts
- Who runs it
- Edwards Lifesciences
- Where
- China14 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 250 people enrolled
- Started
- 24 Jan 2022
- Expected to end
- Dec 2035
- Type of study
- Observational
- Treatments tested
- SAPIEN 3 Transcatheter Heart Valve
- Record updated
- 12 August 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Patient with symptomatic, severe, calcified aortic stenosis who is appropriate for the treatment with transcatheter aortic valve replacement as determined by a heart team and will undergo TAVI with the Edwards SAPIEN 3 System as part of standard-of-care treatment
- All surgical risks as determined by the site Heart Team
- The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent
Who cannot take part
- Active SARS-CoV-2 infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
- Participating in a drug or device study that has not reached its primary endpoint
- Medical, social, or psychological conditions that preclude appropriate consent and follow-up, including subjects under guardianship
- Evidence of intracardiac mass, thrombus, vegetation, active infection or endocarditis
- Considered to be part of a vulnerable population
- Pre-existing mechanical or bioprosthetic aortic valve
- Cannot tolerate an anticoagulation/antiplatelet regimen
- Tortuous or calcified vessels that would prevent safe entry of the dilators and sheath
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objective of this study is to evaluate the long term safety and effectiveness of the SAPIEN 3 Transcatheter Heart Valve system in real world setting.
The group in the trial
- Transcatheter Aortic Valve Implantation (TAVI)
Treatment: SAPIEN 3 Transcatheter Heart Valve
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- SAPIEN 3 China Post Market Registry Study
- Record updated
- 12 August 2026